Related references
Note: Only part of the references are listed.Monoclonal antibodies for the treatment of cancer
Casey W. Shuptrine et al.
SEMINARS IN CANCER BIOLOGY (2012)
Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma
Liping Yu et al.
Journal of Cancer (2012)
Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Mark Allegretta et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2011)
Advances in Liver Cancer Antibody Therapies A Focus on Glypican-3 and Mesothelin
Mitchell Ho
BIODRUGS (2011)
Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma
Shiro Suzuki et al.
CANCER SCIENCE (2011)
Glypican-3: A new target for cancer immunotherapy
Mitchell Ho et al.
EUROPEAN JOURNAL OF CANCER (2011)
Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro
Mingqian Feng et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization
Kiyotaka Nakano et al.
ANTI-CANCER DRUGS (2010)
Have we overestimated the benefit of human(ized) antibodies?
Daniel R. Getts et al.
MABS (2010)
Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells
Kiyotaka Nakano et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Mouse monoclonal antibodies in biological research: strategies for high-throughput production
Pieranna Chiarella et al.
BIOTECHNOLOGY LETTERS (2008)
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2008)
Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
H Komori et al.
CLINICAL CANCER RESEARCH (2006)
Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling
MI Capurro et al.
CANCER RESEARCH (2005)
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin
M Ho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma
Y Hippo et al.
CANCER RESEARCH (2004)
Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice
T Nakatsura et al.
CLINICAL CANCER RESEARCH (2004)
Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
M Capurro et al.
GASTROENTEROLOGY (2003)
Share Paper
